The thin-film freezing specialist reports positive safety and pharmacokinetic data coming out of the Phase I trial of its niclosamide inhalation powder.
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientific’s Nantheia ATL5, a candidate for treating opioid use disorder.
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
Australia-based Nucleus Network has acquired an early-phase clinical research organization in the US, which has a broad range of access to specialist patient populations, says CEO.
Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.
The Phase I clinical trial is slated for early 2020 and will be first CAR-T cell therapy clinical trial to use Horizon Discovery’s technology, according to the company.
Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.
Previous setbacks in Alzheimer’s disease research for disease-modifying treatments have set the stage for a pipeline of new medicines now moving into clinical trials, according to a recent PhRMA report.
Impel Neuropharma announced the first participant have been dosed in a Phase I trial looking at safety and tolerability for the company’s intranasal olanzapine product.